Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Osiris Therapeutics, Inc.    

OSIRIS THERAPEUTICS, INC.
Mes dernières consult.
Most popular
Report
 SummaryChartsNewsCalendarCompanyFinancials 
Company
Osiris Therapeutics, Inc. engages in stem cell research and development of pharmaceutical products.Its regenerative medicine targets dermal burns, pressure ulcers, venous leg, diabetic foot ulcers, as well as tissue and bone repair.The company was founded by Peter A. Friedli and James S. Burns on... 
More about the company
Latest news on OSIRIS THERAPEUTICS, INC.
2017 OSIRIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
2017 OSIRIS THERAPEUTICS, INC. : Other Events (form 8-K)
2017 OSIRIS THERAPEUTICS : Former Chief Financial Officer of Osiris Therapeutics, Inc..
2017 OSIRIS THERAPEUTICS : Announces Resolution of SEC Investigation
2017 OSIRIS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and E..
2017 OSIRIS THERAPEUTICS : SEC charges Osiris Therapeutics and four former executives..
2017 OSIRIS THERAPEUTICS : SEC Charges Biotech Company, Executives With Accounting Fr..
2017 Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
2017 OSIRIS THERAPEUTICS : Provides Update on Audit of 2015 and 2016 Financial Statem..
2017 OSIRIS THERAPEUTICS : SEC Charges Biotech Company, Executives With Accounting Fr..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/02 OSIRIS THERAPEUTICS : Solutions To Challenging Problems
2017 OSIRIS THERAPEUTICS : Expecting Better In 2018
2017 Osiris settles SEC inquiry into accounting practices with $1.5M penalty
2017 MANNKIND : 2nd Short Opportunity
2017 TACTILE SYSTEMS : Multiple Near-Term Catalysts For 75% Downside
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | US68827R1086 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Linda Palczuk President & Chief Executive Officer
Peter A. Friedli Chairman
Frank D. Czworka Chief Operating Officer
Linda L. Chang Chief Financial Officer
Alla Danilkovitch Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OSIRIS THERAPEUTICS, INC.0.00%252
GILEAD SCIENCES12.02%104 801
REGENERON PHARMACEUTICALS-1.53%39 775
VERTEX PHARMACEUTICALS3.90%39 380
GENMAB12.29%11 532
EXELIXIS, INC.-2.47%8 772